Tear metabolomics for the diagnosis of primary open-angle glaucoma
Por:
M. BOTELLO-MARABOTTO, M. MARTINEZ-BISBAL, M. PIAZO-DURAN and R. MARTINEZ-MANEZ
Publicada:
1 jun 2024
Ahead of Print:
1 mar 2024
Resumen:
Primary Open-Angle Glaucoma (POAG) is the most prevalent glaucoma type, and the leading cause of irreversible visual impairment and blindness worldwide. Identification of early POAG biomarkers is of enormous value, as there is not an effective treatment for the glaucomatous optic nerve degeneration (OND). In this pilot study, a metabolomic analysis, by using proton (1H) nuclear magnetic resonance (NMR) spectroscopy was conducted in tears, in order to determine the changes of specific metabolites in the initial glaucoma eyes and to discover potential diagnostic biomarkers. A classification model, based on the metabolomic fingerprint in tears was generated as a non-invasive tool to support the preclinical and clinical POAG diagnosis. 1H NMR spectra were acquired from 30 tear samples corresponding to the POAG group (n = 11) and the control group (n = 19). Data were analysed by multivariate statistics (partial least squares-discriminant analysis: PLS-DA) to determine a model capable of differentiating between groups. The whole data set was split into calibration (65%)/validation (35%), to test the performance and the ability for glaucoma discrimination. The calculated PLS-DA model showed an area under the curve (AUC) of 1, as well as a sensitivity of 100% and a specificity of 83.3% to distinguish POAG group versus control group tear data. This model included 11 metabolites, potential biomarkers of the disease. When comparing the study groups, a decrease in the tear concentration of phenylalanine, phenylacetate, leucine, n-acetylated compounds, formic acid, and uridine, was found in the POAG group. Moreover, an increase in the tear concentration of taurine, glycine, urea, glucose, and unsaturated fatty acids was observed in the POAG group. These results highlight the potential of tear metabolomics by 1H NMR spectroscopy as a non-invasive approach to support early POAG diagnosis and in order to prevent visual loss.
Filiaciones:
M. BOTELLO-MARABOTTO:
Univ Valencia, Univ Politecn Valencia, Inst Interuniv Invest Reconocimiento Mol & Desarro, Valencia, Spain
Univ Politecn Valencia, Inst Invest Sanitaria La Fe IISLAFE, Unidad Mixta Invest Nanomed & Sensores, Valencia, Spain
Inst Salud Carlos III, CIBER Bioingn Biomat & Nanomed, Madrid, Spain
:
Univ Valencia, Univ Politecn Valencia, Inst Interuniv Invest Reconocimiento Mol & Desarro, Valencia, Spain
Univ Politecn Valencia, Inst Invest Sanitaria La Fe IISLAFE, Unidad Mixta Invest Nanomed & Sensores, Valencia, Spain
Inst Salud Carlos III, CIBER Bioingn Biomat & Nanomed, Madrid, Spain
Univ Valencia, Dept Quim Fis, C Doctor Moliner 50, Valencia 46100, Spain
M. PIAZO-DURAN:
Ophthalm Res Unit Santiago Grisolia FISABIO, Valencia, Spain
Univ Valencia, Cellular & Mol Ophthalmobiol Res Grp, Valencia, Spain
Inst Hlth Carlos III, Spanish Net Inflammatory Res REI RICORS RD21 0002, Madrid, Spain
R. MARTINEZ-MANEZ:
Univ Valencia, Univ Politecn Valencia, Inst Interuniv Invest Reconocimiento Mol & Desarro, Valencia, Spain
Univ Politecn Valencia, Inst Invest Sanitaria La Fe IISLAFE, Unidad Mixta Invest Nanomed & Sensores, Valencia, Spain
Inst Salud Carlos III, CIBER Bioingn Biomat & Nanomed, Madrid, Spain
Univ Politecn Valencia, Dept Quim, Valencia, Spain
Univ Politecn Valencia, Ctr Invest Principe Felipe, Unidad Mixta UPV CIPF Invest Mecanismos Enfermedad, Valencia, Spain
hybrid
|